| Epigenetics in health and disease L Zhang, Q Lu, C Chang Epigenetics in allergy and autoimmunity, 3-55, 2020 | 563 | 2020 |
| Clinical significance of miRNAs in autoimmunity L Zhang, H Wu, M Zhao, C Chang, Q Lu Journal of autoimmunity 109, 102438, 2020 | 88 | 2020 |
| Integrative epigenetic analysis reveals therapeutic targets to the DNA methyltransferase inhibitor guadecitabine (SGI‐110) in hepatocellular carcinoma M Liu, L Zhang, H Li, T Hinoue, W Zhou, H Ohtani, A El‐Khoueiry, ... Hepatology 68 (4), 1412-1428, 2018 | 61 | 2018 |
| DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma L Zhang, HT Li, R Shereda, Q Lu, DJ Weisenberger, C O'Connell, ... Cancer letters 548, 215899, 2022 | 41 | 2022 |
| Identifying the differentially expressed microRNAs in autoimmunity: a systemic review and meta-analysis L Zhang, H Wu, M Zhao, Q Lu Autoimmunity 53 (3), 122-136, 2020 | 36 | 2020 |
| ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma M Li, C Sun, X Bu, Y Que, L Zhang, Y Zhang, L Zhang, S Lu, J Huang, ... Cell death & disease 12 (6), 620, 2021 | 27 | 2021 |
| IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma C Sun, M Li, L Zhang, F Sun, H Chen, Y Xu, Y Lan, L Zhang, S Lu, J Zhu, ... Cell Death & Disease 13 (6), 572, 2022 | 12 | 2022 |
| Combination therapy with anti-PD-1 or PD-1 antibody alone in asian pediatric patients with relapsed or refractory cancer Y Que, J Wang, J Zhu, N Li, J Huang, S Lu, F Sun, L Zhang, Z Zhen, ... Frontiers in Immunology 12, 647733, 2021 | 9 | 2021 |
| A pan-cancer analysis of IRAK1 expression and their association with immunotherapy response M Liu, Y Que, Y Hong, L Zhang, X Zhang, Y Zhang Frontiers in Molecular Biosciences 9, 904959, 2022 | 6 | 2022 |
| Influence of UGT1A1* 6/* 28 polymorphisms on irinotecan-related toxicity and survival in pediatric patients with relapsed/refractory solid tumors treated with the VIT regimen X Zhu, J Zhu, F Sun, Z Zhen, D Zhou, S Lu, J Huang, Y Que, L Zhang, ... Pharmacogenomics and Personalized Medicine, 369-377, 2021 | 6 | 2021 |
| Irinotecan plus doxorubicin hydrochloride liposomes for relapsed or refractory wilms tumor J Wang, L Zhang, L Guo, Y Que, Y Zhang, F Sun, J Zhu, S Lu, J Huang, ... Frontiers in Oncology 11, 721564, 2021 | 4 | 2021 |
| The efficacy and safety of anlotinib in pediatric patients with refractory or recurrent Solid tumors S Lu, Y Hong, H Chen, L Wu, F Sun, J Wang, J Zhu, Y Que, L Zhang, ... Frontiers in Pharmacology 13, 711704, 2022 | 3 | 2022 |
| Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory neuroblastoma. J Zhu, Z Zhen, J Wang, T Chen, S Lu, F Sun, J Huang, Y Que, L Zhang, ... Journal of Clinical Oncology 39 (15_suppl), e22009-e22009, 2021 | 1 | 2021 |
| Combination therapy with anti-PD-1 or PD-1 antibody alone in pediatric patients with relapsed or refractory cancer. Y Que, J Wang, J Zhu, N Li, J Huang, S Lu, F Sun, L Zhang, Z Zhen, ... Journal of Clinical Oncology 39 (15_suppl), e22004-e22004, 2021 | 1 | 2021 |
| Psychological programs to improve the life quality and psychosocial behavior of pediatric cancer patients W Liuhong, L Zhang, J Wang, Y Que, F Sun, J Zhu, SY Lu, J Huang, ... Authorea Preprints, 2024 | | 2024 |
| Immune‐Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney Y Hong, Y Que, Y Hu, B Shi, J Zhu, J Wang, J Huang, F Sun, L Zhang, ... Disease Markers 2022 (1), 4752184, 2022 | | 2022 |
| Clinical value of Next Generation Sequencing in Chinese pediatric soft tissue sarcoma: A multicenter data. S Lu, F Sun, X Yuan, J Huang, J Wang, H Guo, Z Zhen, J Zhu, X Sun, ... Journal of Clinical Oncology 39 (15_suppl), e22005-e22005, 2021 | | 2021 |
| Clinical significance of next-generation sequencing in Chinese patients with relapsed/refractory Wilm’s tumor. J Wang, F Sun, W Hu, L Zhang, Q Wang, Z Zhen, J Zhu, S Lu, J Huang, ... Journal of Clinical Oncology 39 (15_suppl), e22003-e22003, 2021 | | 2021 |
| The efficacy and safety of anlotinib in refractory/recurrent/advanced pediatric solid tumors: A retrospective study. S Lu, Y Hong, H Chen, L Wu, J Zhu, J Wang, F Sun, Z Zhen, Y Que, ... Journal of Clinical Oncology 39 (15_suppl), 11556-11556, 2021 | | 2021 |
| Prognostic nomogram for pediatric nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Y Zhang, Y Hong, H Chen, Y Wu, J Zhu, J Huang, J Wang, F Sun, Y Que, ... Journal of Clinical Oncology 39 (15_suppl), e18036-e18036, 2021 | | 2021 |
